Review





Similar Products

mouse anti hla dr dp dq  (Absolute Biotech Inc)
86
Absolute Biotech Inc mouse anti hla dr dp dq
Mouse Anti Hla Dr Dp Dq, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/anti+dp+dq+dr+hla+mouse/pmc13130630-39-0-5
Average 86 stars, based on 1 article reviews
mouse anti hla dr dp dq - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
anti pan hla ii β monoclonal antibody  (Bio-Rad)
93
Bio-Rad anti pan hla ii β monoclonal antibody
Anti Pan Hla Ii β Monoclonal Antibody, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/Mouse+anti+Human+HLA+DP+DQ+DR/pmc12778896-93-8-18
Average 93 stars, based on 1 article reviews
anti pan hla ii β monoclonal antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
monoclonal mouse anti-human hla-dr/dp/dq/dx antibody clone.cr3/43  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology monoclonal mouse anti-human hla-dr/dp/dq/dx antibody clone.cr3/43
KAT2B Regulates <t>tsMHC-II</t> Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels <t>of</t> <t>HLA-DR,</t> DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC
Monoclonal Mouse Anti Human Hla Dr/Dp/Dq/Dx Antibody Clone.Cr3/43, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/monoclonal+mouse+anti+human+hla+dr+dp+dq+dx+antibody+clone+cr3+43/pmc12150567-269-10-19
Average 90 stars, based on 1 article reviews
monoclonal mouse anti-human hla-dr/dp/dq/dx antibody clone.cr3/43 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mouse anti-human hla-dq, dp, dr (fitc)  (Becton Dickinson)
90
Becton Dickinson mouse anti-human hla-dq, dp, dr (fitc)
KAT2B Regulates <t>tsMHC-II</t> Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels <t>of</t> <t>HLA-DR,</t> DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC
Mouse Anti Human Hla Dq, Dp, Dr (Fitc), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/hladr+antibody/pm40299654-84-38-41
Average 90 stars, based on 1 article reviews
mouse anti-human hla-dq, dp, dr (fitc) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti pan hla ii β mab  (Bio-Rad)
93
Bio-Rad anti pan hla ii β mab
KAT2B Regulates <t>tsMHC-II</t> Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels <t>of</t> <t>HLA-DR,</t> DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC
Anti Pan Hla Ii β Mab, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/Mouse+anti+Human+HLA+DP+DQ+DR/pm40186192-66-15-23
Average 93 stars, based on 1 article reviews
anti pan hla ii β mab - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
wr18  (Bio-Rad)
93
Bio-Rad wr18
KAT2B Regulates <t>tsMHC-II</t> Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels <t>of</t> <t>HLA-DR,</t> DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC
Wr18, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/Mouse+anti+Human+HLA+DP+DQ+DR/pmc12039470-24-44-45
Average 93 stars, based on 1 article reviews
wr18 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
mouse monoclonal anti hla class dr dp dq  (Danaher Inc)
86
Danaher Inc mouse monoclonal anti hla class dr dp dq
KAT2B Regulates <t>tsMHC-II</t> Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels <t>of</t> <t>HLA-DR,</t> DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC
Mouse Monoclonal Anti Hla Class Dr Dp Dq, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+hla+dq+dr+dp/pmc11288375-28-0-10
Average 86 stars, based on 1 article reviews
mouse monoclonal anti hla class dr dp dq - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


KAT2B Regulates tsMHC-II Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels of HLA-DR, DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC

Journal: Biomarker Research

Article Title: Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

doi: 10.1186/s40364-025-00797-9

Figure Lengend Snippet: KAT2B Regulates tsMHC-II Function as a Dual-Effect Biomarker for Anthracycline Chemotherapy Exemption and Immunotherapy Benefit. A Flow cytometry peak plots showing the protein expression levels of HLA-DR, DQ, and DP in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157). B ATAC-seq peak plots of the CIITA gene in TNBC cell lines (MDA-MB-231, BT-549, MDA-MB-468, MDA-MB-157), with the promoter region highlighted in red shading. C ATAC-seq peak plots near transcription start sites (TSS) comparing TNBC cell lines with high versus low tsMHC-II expression. D Schematic diagram and Venn diagram illustrating the identification of KAT2B as a regulatory gene for tsMHC-II, screened by integrating TCGA database, TNBC cell line ATAC-seq data, and the Curtis’s anthracycline chromatin therapeutic efficacy-related database. E ATAC-seq peak plots of KAT2B and ChIP-seq peak plots of H4K8ac and H3K14ac at the CIITA gene in TNBC cell lines with high versus low tsMHC-II expression, with the CIITA promoter region highlighted in red. F Pearson correlation scatter plot of CIITA and KAT2B expression levels in the TCGA BRCA database. G Enrichment map of upregulated pathways in the KAT2B high-expression group from GSEA analysis of the TCGA BRCA database. H Bar graph showing differences in cell subpopulation proportions between KAT2B high- and low-expression groups in the TCGA BRCA database, analyzed using EPIC

Article Snippet: All the antibodies used in this study were as follows: tsMHC-II: Monoclonal Mouse Anti-Human HLA-DR/DP/DQ/DX Antibody (Clone.CR3/43, 1:1000, sc-53302, Santa-Cruz); PanCK: Monoclonal Mouse Anti-Human Cytokeratin Antibody (Clone.AE1/AE3, GA053, 1:100, Dako); tsMHC-I: Monoclonal Mouse Anti-HLA Class 1 ABC Antibody (Clone.EMR8-5, ab70328, 1:200, Abcam); CD4: Monoclonal Mouse Anti-Human CD4 Antibody (Clone.4B12, IR649, 1:100, Dako); CD8: Monoclonal Mouse Anti-Human CD8 Antibody (Clone.C8/144B, IR623, 1:150, Dako).

Techniques: Biomarker Discovery, Flow Cytometry, Expressing, Drug discovery, ChIP-sequencing

KAT2B Acetylation of CIITA Promoter Upregulates Tumor-Specific MHC-II Expression Enhancing NAC-IT Efficacy. A Relative RNA expression of KAT2B and CIITA in MDA-MB-231 cells with KAT2B knockdown versus control group (Left); Relative RNA expression of KAT2B and CIITA in BT-549 and MDA-MD-157 cells with KAT2B overexpression versus control group (Right). B Flow cytometry analysis showing proportion of tsMHC-II positive tumor cells in MDA-MB-231 with KAT2B knockdown versus control group (Left); Proportion of tsMHC-II positive tumor cells in BT-549 and MDA-MD-157 with KAT2B overexpression versus control group (Right). C. Radar plots of flow cytometry data for MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. D. Western Blot analysis of KAT2B, CIITA, HLA-DR, and Beta-Actin protein expression in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. E. Schematic diagram of ChIP-qPCR primer design for the 1000 bp CIITA promoter fragments. F. ChIP-qPCR bar graph showing KAT2B binding enrichment at CIITA promoter fragments P1, P2, P3, and P4. G-H. ChIP-qPCR bar graphs showing enrichment of KAT2B, H3K14ac, and H4K8ac at the CIITA promoter P1 segment in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. I. Fluorescence imaging results of co-culture between tsMHC-II high-expression TNBC PDOs and paired CD44 + CD4 + effector T cells. Red indicates CD44 + CD4 + effector T cells, and green represents tsMHC-II high-expression TNBC PDOs. Scale bar: 50 μm. J-K. Tumor viability ( J ) and IFN-γ + CD4 + T-cell proportion ( K ) in PDO immune co-culture groups treated with paclitaxel, doxorubicin, or aPD1, respectively. *means p < 0.05; **means p < 0.01; ***means p < 0.001

Journal: Biomarker Research

Article Title: Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

doi: 10.1186/s40364-025-00797-9

Figure Lengend Snippet: KAT2B Acetylation of CIITA Promoter Upregulates Tumor-Specific MHC-II Expression Enhancing NAC-IT Efficacy. A Relative RNA expression of KAT2B and CIITA in MDA-MB-231 cells with KAT2B knockdown versus control group (Left); Relative RNA expression of KAT2B and CIITA in BT-549 and MDA-MD-157 cells with KAT2B overexpression versus control group (Right). B Flow cytometry analysis showing proportion of tsMHC-II positive tumor cells in MDA-MB-231 with KAT2B knockdown versus control group (Left); Proportion of tsMHC-II positive tumor cells in BT-549 and MDA-MD-157 with KAT2B overexpression versus control group (Right). C. Radar plots of flow cytometry data for MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. D. Western Blot analysis of KAT2B, CIITA, HLA-DR, and Beta-Actin protein expression in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. E. Schematic diagram of ChIP-qPCR primer design for the 1000 bp CIITA promoter fragments. F. ChIP-qPCR bar graph showing KAT2B binding enrichment at CIITA promoter fragments P1, P2, P3, and P4. G-H. ChIP-qPCR bar graphs showing enrichment of KAT2B, H3K14ac, and H4K8ac at the CIITA promoter P1 segment in MDA-MB-231 with KAT2B knockdown, BT-549 and MDA-MD-157 with KAT2B overexpression compared to their respective control groups. I. Fluorescence imaging results of co-culture between tsMHC-II high-expression TNBC PDOs and paired CD44 + CD4 + effector T cells. Red indicates CD44 + CD4 + effector T cells, and green represents tsMHC-II high-expression TNBC PDOs. Scale bar: 50 μm. J-K. Tumor viability ( J ) and IFN-γ + CD4 + T-cell proportion ( K ) in PDO immune co-culture groups treated with paclitaxel, doxorubicin, or aPD1, respectively. *means p < 0.05; **means p < 0.01; ***means p < 0.001

Article Snippet: All the antibodies used in this study were as follows: tsMHC-II: Monoclonal Mouse Anti-Human HLA-DR/DP/DQ/DX Antibody (Clone.CR3/43, 1:1000, sc-53302, Santa-Cruz); PanCK: Monoclonal Mouse Anti-Human Cytokeratin Antibody (Clone.AE1/AE3, GA053, 1:100, Dako); tsMHC-I: Monoclonal Mouse Anti-HLA Class 1 ABC Antibody (Clone.EMR8-5, ab70328, 1:200, Abcam); CD4: Monoclonal Mouse Anti-Human CD4 Antibody (Clone.4B12, IR649, 1:100, Dako); CD8: Monoclonal Mouse Anti-Human CD8 Antibody (Clone.C8/144B, IR623, 1:150, Dako).

Techniques: Expressing, RNA Expression, Knockdown, Control, Over Expression, Flow Cytometry, Western Blot, ChIP-qPCR, Binding Assay, Fluorescence, Imaging, Co-Culture Assay